Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SLN360 · 1 trial · 3 indications
safety and tolerability will be reported separately following single-dose administration.
| Arm | Type | Description |
|---|---|---|
| 30 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| 100 mg | EXPERIMENTAL | - |
| 300 mg | EXPERIMENTAL | - |
| 600 mg | EXPERIMENTAL | - |
| 900 mg | EXPERIMENTAL | - |
| 100 mg multi dose | EXPERIMENTAL | - |
| 200 mg multi dose | EXPERIMENTAL | - |
| 300 mg multi dose | EXPERIMENTAL | - |
| 600 mg multi dose | EXPERIMENTAL | - |
| Placebo multi dose | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| SLN360 | DRUG | SLN360 for subcutaneous (s.c.) injection |
| Placebo | DRUG | Sodium chloride for subcutaneous (s.c.) injection |
Inclusion criteria: * Elevated plasma Lp(a) ≥ 150nmol/L. * All subjects must agree to adhere to appropriate contraception requirements. * Subjects must provide written informed consent and be able to comply with all study requirements. * Body mass index of ≥ 18 kg/m2 and ≤ 45 kg/m2. * For the MD pa...
SLN360 is an investigational drug being studied for the treatment of hyperlipidemias, specifically elevated lipoprotein(a) levels. It is being developed as a potential therapy for patients with dyslipidemias and elevated Lp(a), a condition associated with increased cardiovascular risk.
SLN360 is a small molecule designed to target elevated lipoprotein(a), a type of lipid in the blood. By addressing elevated Lp(a) levels, it aims to treat hyperlipidemias and dyslipidemias, potentially reducing cardiovascular risk associated with this condition.
SLN360 is being developed by Silence Therapeutics Plc, a biopharmaceutical company. The company's American Depository Shares are traded under the ticker symbol SLN on the NASDAQ stock exchange.
SLN360 is currently in Phase 1 clinical development. It has completed one Phase 1 trial, and the drug remains investigational, meaning it has not yet been approved by regulatory authorities and is still undergoing clinical evaluation.
SLN360 has been studied in a Phase 1 clinical trial with the identifier NCT04606602. This completed trial investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of SLN360 in subjects with elevated lipoprotein(a). The study enrolled 70 participants across the United States, Australia, Netherlands, and United Kingdom.
SLN360 is a unique investigational drug candidate developed by Silence Therapeutics. It is not known to be the same as any other approved or investigational medication, as it is specifically designed to target elevated lipoprotein(a) levels for the treatment of hyperlipidemias.